Denali Therapeutics Inc. (DNLI) SEC Filings & Earnings Calls

Dependence on AVLAYAH launch success; pipeline clinical risk.

“AVLAYAH is first commercial product; pipeline programs still in early stages.”

Pipeline setback: DNL151 Phase 2b failure

“In May 2026, we and Biogen announced topline results from the Phase 2b LUMA study of BIIB122/DNL151 in individuals with early-stage Parkinson's disease. The LUMA study did not meet its primary or secondary endpoints, and we and Biogen decided to discontinue further development of BIIB122/DNL151 in idiopathic Parkinson's disease.” · word for word

Collaboration termination: Takeda exits DNL593

“In April 2026, we received notification from Takeda of its decision to terminate the collaboration agreement to co-develop and co-commercialize DNL593 (PTV:PGRN) for FTD-GRN.” · word for word

Commercial execution risk for AVLAYAH

“Although we expect AVLAYAH product revenue to contribute to funding our operations, we do not expect such revenue to be sufficient to offset our operating expenses in the near term.” · word for word

No material risks; PRV sale is a one-time event.

Transaction subject to HSR clearance; closing not guaranteed.

“The transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.” · word for word

Clinical trial failure eliminates a major pipeline asset for Denali, reducing future revenue potential and increasing reliance on remaining programs.

“Phase 2b LUMA study did not meet its primary or secondary endpoints; development discontinued”

Takeda collaboration termination

“In April 2026, Takeda notified the Company of its decision to terminate the collaboration agreement related to PTV:PGRN.” · word for word

Continued approval contingent on confirmatory trial

“Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.” · word for word

No product revenue yet

“The Company had not recorded milestone revenue or product sales under the Biogen Collaboration Agreement.”

Commercial execution risk: AVLAYAH is first commercial product; reimbursement and market adoption uncertain.

“AVLAYAH launched in U.S. with strong momentum... first patients treated in commercial setting in April.” · word for word

Pipeline dependency: DNL593 data expected end-2026; Takeda termination may slow development.

“Denali continues to advance DNL593 in the ongoing Phase 1/2 study... expects results by the end of 2026.” · word for word

Clinical trial failure risk

“Continued approval for this indication may be contingent on verification of clinical benefit in a confirmatory trial.” · word for word

Key executive departure

“Carole Ho, M.D. resigned from her role as Chief Medical Officer and Head of Development on November 14, 2025.”

Dependence on single product approval

“The royalty payments to Royalty Pharma will cease upon reaching a multiple of 3.0x, or 2.5x if achieved by the first quarter of 2039.” · word for word

Loss of partner support for DNL593 program; potential development delay.

“Takeda terminated co-development/co-commercialization agreement.”

Royalty obligation may reduce future product revenue upside; synthetic royalty terms not disclosed.

“synthetic royalty funding agreement between the Company and Royalty Pharma” · word for word

Continued approval contingent on confirmatory trial; accelerated approval based on surrogate endpoint

“Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial” · word for word

Clinical Hold for DNL952

“In December 2025, we announced that the IND application for the Phase 1 study of DNL952 has been placed on clinical hold.” · word for word

PRV Eligibility Uncertainty

“Because we submitted a filing of our intent to request a PRV after the initial BLA submission, based on discussions with the FDA, we may not be eligible to receive the PRV.” · word for word

Regulatory Delay for Tividenofusp Alfa

“In October 2025, we announced that the FDA had extended its review timeline of the BLA and assigned a new PDUFA target date of April 5, 2026.” · word for word

Infusion-Related Reactions

“The pause was based on infusion-related reactions reported in two study participants, one Grade 2 and one Grade 3 in severity and both deemed serious adverse events.” · word for word

Regulatory and commercial risk; no approved products yet; net loss increasing

“Net loss increased to $512.5M from $422.8M; all value depends on FDA approval and commercial success of tividenofusp alfa”

Regulatory and clinical risk: FDA may not approve tividenofusp alfa; clinical trial results may not meet endpoints

“uncertainties related to the FDA’s policies and accelerated approval program, including risks that the PDUFA action date may be extended and the FDA may not approve tividenofusp alfa” · word for word

Dilution risk from equity offering

“Issuance of 9,142,857 shares plus pre-funded warrants and potential additional shares”

Regulatory risk: FDA accelerated approval required by June 30, 2026 for initial payment; EMA approval by Dec 31, 2029 for milestone.

“Transaction subject to FDA accelerated approval on or before June 30, 2026.”

Clinical and regulatory risks inherent in biotech pipeline; no specific financial impact.

“Forward-looking statements include risks related to clinical trials, regulatory approvals, and commercial launch.”

Clinical trial and regulatory risk

“The company is a clinical-stage biopharmaceutical company with no approved products; its success depends on clinical trial outcomes and regulatory approvals.”

Collaboration dependency

“Termination of ATV:TREM2 program by Takeda and termination of ATV:Abeta license by Biogen; future milestone and royalty payments from these programs are no longer expected.”

Cash burn and dilution risk

“Net cash used in operating activities $314.1 million for 9M 2025; company may need to raise additional capital.”